Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.

Konstantin Schlick; Dominik Kiem; Richard Greil

doi:10.3390/biom11101469

Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.

Konstantin Schlick (First author), Dominik Kiem (Co-author), Richard Greil^* (Last author)

^*Corresponding author for this work

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Review article › peer-review

11 Citations (Web of Science)

Original language	English
Journal	Biomolecules
Volume	11
Issue number	10
DOIs	https://doi.org/10.3390/biom11101469
Publication status	Published - 2021

Keywords

PHASE-III TRIAL
POSITIVE SOLID TUMORS
NAB-PACLITAXEL
GEMCITABINE
ADENOCARCINOMA
SURVIVAL
COMBINATION
ERLOTINIB
PD-1
LAROTRECTINIB

Access to Document

10.3390/biom11101469

Cite this

@article{f3baccfbff424e9881b9ba78302eddd1,

title = "Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.",

keywords = "PHASE-III TRIAL, POSITIVE SOLID TUMORS, NAB-PACLITAXEL, GEMCITABINE, ADENOCARCINOMA, SURVIVAL, COMBINATION, ERLOTINIB, PD-1, LAROTRECTINIB",

author = "Konstantin Schlick and Dominik Kiem and Richard Greil",

note = "all: Paracelsus Med Univ, Oncol Ctr, Dept Internal Med Haematol Med Oncol Haemostaseol, A-5020 Salzburg, Austria; ",

year = "2021",

doi = "10.3390/biom11101469",

language = "English",

volume = "11",

journal = "Biomolecules",

issn = "2218-273X",

publisher = "MDPI",

number = "10",

}

TY - JOUR

T1 - Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.

AU - Schlick, Konstantin

AU - Kiem, Dominik

AU - Greil, Richard

N1 - all: Paracelsus Med Univ, Oncol Ctr, Dept Internal Med Haematol Med Oncol Haemostaseol, A-5020 Salzburg, Austria;

PY - 2021

Y1 - 2021

KW - PHASE-III TRIAL

KW - POSITIVE SOLID TUMORS

KW - NAB-PACLITAXEL

KW - GEMCITABINE

KW - ADENOCARCINOMA

KW - SURVIVAL

KW - COMBINATION

KW - ERLOTINIB

KW - PD-1

KW - LAROTRECTINIB

U2 - 10.3390/biom11101469

DO - 10.3390/biom11101469

M3 - Review article

C2 - 34680101

SN - 2218-273X

VL - 11

JO - Biomolecules

JF - Biomolecules

IS - 10

ER -